Anixa Biosciences, Inc.

NasdaqCM ANIX

Anixa Biosciences, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending July 31, 2024: USD -8.38 M

Anixa Biosciences, Inc. Free Cash Flow is USD -8.38 M for the Trailing 12 Months (TTM) ending July 31, 2024, a -43.61% change year over year. Free cash flow is the amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

Anixa Biosciences, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending July 31, 2023 was USD -5.83 M, a 1.85% change year over year.
Anixa Biosciences, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending July 31, 2022 was USD -5.94 M, a -8.72% change year over year.
Anixa Biosciences, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending July 31, 2021 was USD -5.47 M, a 7.96% change year over year.
Anixa Biosciences, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending July 31, 2020 was USD -5.94 M, a -28.90% change year over year.

Key data

Date	Free Cash Flow	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities

NasdaqCM: ANIX

Anixa Biosciences, Inc.

CEO	Dr. Amit Kumar Ph.D.
IPO Date	Oct. 7, 1983
Location	United States
Headquarters	3150 Almaden Expressway
Employees	4
Sector	Health Care
Industries Biotechnology Pharmaceuticals Vaccines

Description

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

Key trends

Past 5 years